Guillem Laporta combines biotech and finance training as a CFA charterholder, and built his career at specialist healthcare investors like Caixa Capital Risc, Andera Partners in Paris, and now Ysios, working on deals across Europe and the U.S. tied to companies like ReViral, Axonics, Sanifit, and Verona Pharma, while also serving on company boards and staying involved in Catalonia's biotech community.
About their Fund
Ysios Capital is Spain's largest life sciences venture capital firm, with ties to Spain's science leadership through cofounder Cristina Garmendia, who left the firm to serve as Spain's Minister of Science and Innovation before returning as a partner, and it has moved beyond typical venture investing into company creation through its InceptionBio vehicle, which builds biotech companies from early tech-transfer projects with a strong focus on Spain. The firm focuses on hard science areas like gene therapy, oncology, orphan CNS disease, calcification disorders, and regenerative cardiovascular implants, has backed deals such as Sanifit's acquisition by Vifor Pharma and U.S.-based Kala Pharmaceuticals, and produced three NASDAQ IPOs in 2021 alongside its oversubscribed €216M third fund.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































